Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
de Berker  D.  Clinical practice: fungal nail disease.  N Engl J Med. 2009;360(20):2108-2116.PubMedGoogle ScholarCrossref
Elewski  BE, Charif  MA.  Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions.  Arch Dermatol. 1997;133(9):1172-1173.PubMedGoogle ScholarCrossref
Gupta  AK, Jain  HC, Lynde  CW, Macdonald  P, Cooper  EA, Summerbell  RC.  Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients.  J Am Acad Dermatol. 2000;43(2, pt 1):244-248.PubMedGoogle ScholarCrossref
Ghannoum  MA, Hajjeh  RA, Scher  R,  et al.  A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.  J Am Acad Dermatol. 2000;43(4):641-648.PubMedGoogle ScholarCrossref
Roberts  DT, Taylor  WD, Boyle  J; British Association of Dermatologists.  Guidelines for treatment of onychomycosis.  Br J Dermatol. 2003;148(3):402-410.PubMedGoogle ScholarCrossref
Mehregan  DR, Gee  SL.  The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents.  Cutis. 1999;64(6):407-410.PubMedGoogle Scholar
American Academy of Dermatology.  Ten things physicians and patients should question. Updated August 19, 2015. Accessed February 1, 2015.
 Pharmacy, $4 prescriptions. Walmart Stores, Inc website. Accessed April 12, 2015.
 Pharmacy, $4 generic drugs. Target Brands Inc website. Accessed April 12, 2015.
National Library of Medicine–National Institute of Diabetes and Digestive and Kidney Disease.  LiverTox: clinical and research information on drug-induced liver injury: drug record: terbinafine. Updated September 30, 2015. Accessed November 12, 2015.
Reisberger  EM, Abels  C, Landthaler  M, Szeimies  RM.  Histopathological diagnosis of onychomycosis by periodic acid–Schiff–stained nail clippings.  Br J Dermatol. 2003;148(4):749-754.PubMedGoogle ScholarCrossref
Lilly  KK, Koshnick  RL, Grill  JP, Khalil  ZM, Nelson  DB, Warshaw  EM.  Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests.  J Am Acad Dermatol. 2006;55(4):620-626.PubMedGoogle ScholarCrossref
Weinberg  JM, Koestenblatt  EK, Tutrone  WD, Tishler  HR, Najarian  L.  Comparison of diagnostic methods in the evaluation of onychomycosis.  J Am Acad Dermatol. 2003;49(2):193-197.PubMedGoogle ScholarCrossref
Haghani  I, Shokohi  T, Hajheidari  Z, Khalilian  A, Aghili  SR.  Comparison of diagnostic methods in the evaluation of onychomycosis.  Mycopathologia. 2013;175(3-4):315-321.PubMedGoogle ScholarCrossref
Lawry  MA, Haneke  E, Strobeck  K, Martin  S, Zimmer  B, Romano  PS.  Methods for diagnosing onychomycosis: a comparative study and review of the literature.  Arch Dermatol. 2000;136(9):1112-1116.PubMedGoogle Scholar
Barak  O, Asarch  A, Horn  T.  PAS is optimal for diagnosing onychomycosis.  J Cutan Pathol. 2010;37(10):1038-1040.PubMedGoogle ScholarCrossref
Williams  R, Cohen  J, Mikailov  A, Laga  A, Mostaghimi  A. Clinical diagnosis of onychomycosis by physicians: is a confirmatory test necessary? Paper presented at: Medical Dermatology Society Annual Meeting; March 19, 2015; San Francisco, CA.
Centers for Medicare & Medicaid Services.  Clinical laboratory fee schedule. Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html. Accessed April 11, 2015.
Centers for Medicare & Medicaid Services.  Physician fee schedule search. Accessed April 11, 2015.
TreePlan Software (for Windows Excel and MacExcel) [computer program]. San Francisco, CA: TreePlan Software; 2015. Accessed October 15, 2014.
Zaias  N, Rebell  G.  The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine.  Arch Dermatol. 2004;140(6):691-695.PubMedGoogle Scholar
Original Investigation
March 2016

Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis

Author Affiliations
  • 1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Department of Biostatistics and Bioinformatics, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana
JAMA Dermatol. 2016;152(3):276-281. doi:10.1001/jamadermatol.2015.4190

Importance  Onychomycosis is the most common disease of the nail in adults. International guidelines urge health care professionals to perform confirmatory diagnostic testing before initiating systemic therapy. This approach was determined to be cost-effective in studies from the late 1990s but has not been evaluated more recently. The effect of testing on the costs of efinaconazole, 10%, topical solution treatment is unknown.

Objective  To evaluate the cost and potential harm associated with 3 approaches to onychomycosis evaluation before treatment with oral terbinafine or efinaconazole, 10%.

Design, Setting, and Participants  A decision analysis that compared the costs of 3 onychomycosis management algorithms based on recently published data of test statistics, disease prevalence, and relevant costs: (1) empirical therapy without confirmatory testing, (2) pretreatment confirmatory testing with potassium hydroxide (KOH) stain followed by periodic acid–Schiff (PAS) evaluation if KOH testing is negative, and (3) pretreatment testing with PAS. There was no direct patient evaluation. Selection of included studies was based on outcome variables and the quality of study design. The study was conducted from April 1, 2014, to September 1, 2015.

Main Outcomes and Measures  Primary outcomes included direct cost of onychomycosis testing and therapy and cost to avoid harm when treating patients with oral terbinafine.

Results  At a disease prevalence of 75%, per-patient cost savings of empirical terbinafine therapy without confirmatory testing was $47 compared with the KOH screening model and $135 compared with PAS testing. The cost of testing necessary to prevent a single case of clinically relevant liver toxic effects related to terbinafine at a prevalence of 75% was between $18.2 million and $43.7 million for KOH screening and between $37.6 million and $90.2 million for PAS testing. At a prevalence of 75%, KOH screening and PAS testing before treatment with efinaconazole, 10%, saved $272 and $406 per patient per nail, respectively.

Conclusions and Relevance  These results show that empirical treatment with terbinafine for patients with suspected onychomycosis is more cost-effective than confirmatory testing across all prevalence of disease, with minimal effect on patient safety. In contrast, confirmatory testing before treatment with efinaconazole, 10%, is associated with reduced costs. Blanket recommendations for confirmatory testing before systemic therapy should be reconsidered and replaced with recommendations tailored to specific therapies.